Get started
Author

Kevinkumar Kansagra

Observed names: Dr. Kevinkumar Kansagra, K. Kansagra, K., Kansagra, Kansagra Kevinkumar, Kevinkumar A. Kansagra, Kevinkumar Ashokbhai Kansagra, Kevinkumar A. Kansagra
ORCID: 0000-0001-9157-498X
Observed ORCID: 0000-0001-9157-498X
OpenAlex ID: A5075430507
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
2022 · Akash Khobragade, Suresh Bhate, et al. · The Lancet · 262
PDF
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
2021 · Taufik Momin, Kevinkumar Kansagra, et al. · EClinicalMedicine · 186
PDF
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)
2022 · Deven V. Parmar, Kevinkumar A. Kansagra, et al. · Clinical Pharmacology in Drug Development · 94
PDF
Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study
2019 · Deven V. Parmar, Kevinkumar A. Kansagra, et al. · American Journal of Nephrology · 77
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study
2021 · Anuja Pandit, Nirav Bhalani, et al. · International Journal of Infectious Diseases · 62
PDF
Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
2013 · Rajendra H. Jani, Kevinkumar Kansagra, et al. · Clinical Drug Investigation · 62
PDF
Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)
2022 · Sishir Gang, Prakash Khetan, et al. · American Journal of Nephrology · 60
A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)
2020 · Kevinkumar Kansagra, Deven Parmar, et al. · Clinical Infectious Diseases · 51
PDF
Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)
2022 · Dhananjai Agrawal, Deepak Varade, et al. · American Journal of Nephrology · 49
Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
2017 · Kevinkumar A. Kansagra, Deven Parmar, et al. · Clinical Pharmacokinetics · 44
PDF
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY‐IL1 in Three Patients with Cryopyrin‐Associated Periodic Syndromes
2023 · Pravin Hissaria, Kevinkumar Kansagra, et al. · Clinical Pharmacology in Drug Development · 32
PDF
Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects
2017 · Maulik R. Patel, Kevinkumar A. Kansagra, et al. · Clinical Drug Investigation · 10
Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study
2022 · Georges F R Radohery, Jeremy Gower, et al. · The Lancet Infectious Diseases · 7
Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease
2025 · Harpreet Kaur, Nilesh Pandey, et al. · Experimental Neurology · 6
PDF
Saroglitazar 4 Mg in Metabolic Dysfunction‐Associated Steatotic Liver Disease: 24‐Week Results From Phase 4 Study
2026 · Arun Sanyal, Soham Doshi, et al. · Liver International · 4
A Phase 3, Randomised, Open-Label, Non-Inferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (Twinrab TM) Against Human Rabies Immunoglobulin (HRIG)
2019 · Kevinkumar Kansagra, Deven Parmar, et al. · SSRN Electronic Journal · 4
A Sensitive Assay for ZYAN1 in Human Whole Blood and Urine Utilizing Positive LC–MS/MS Electrospray Ionization
2017 · Harilal Patel, Krunal Soni, et al. · Bioanalysis · 4
Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC–MS/MS method utilizing electrospray ionization in a positive mode
2016 · Ashok Ghoghari, Ranjeet Dash, et al. · Biomedical Chromatography · 4
Mon-318 a Phase Ii Trial to Assess Safety, Tolerability and Efficacy of Phd-2 Inhibitor (desidustat-zyan1) in the Treatment of Anemia in Pre-dialysis Chronic Kidney Disease Patients
2019 · D. Parmar, K. Kansagra · Kidney International Reports · 2
Mon-319 Comparison of Pharmacokinetic Parameters of Desidustat in Pre-dialysis Chronic Kidney Disease Indian Patients and Australian Healthy Volunteers
2019 · K. Kansagra · Kidney International Reports · 2
Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation
2026 · Mayank Gangwar, Gunjan Kumar, et al. · Trials · 1
A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma
2025 · Chintan Patel, Diptikant Sahoo, et al. · Clinical Therapeutics · 1
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients
2025 · Chintan Patel, Vaishal Sheth, et al. · Respiratory Medicine · 1
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants
2023 · Kevinkumar A. Kansagra, Taufik Momin, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 1
Safety, Tolerability and Pharmacokinetics ofNovel Triaminopyrimidine ZY-19489: A Randomised Double-blind Placebo-control Phase-1 Study among Healthy Indian Participants
2023 · Kevinkumar Kansagra · JOURNAL OF COMMUNICABLE DISEASES · 1
PDF
Works count: 39
Citation count: 1,028
H-index: 11
I10-index: 12
Year
Topic
Type